Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Acute Gouty Arthritis Flares”

19 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 19 of 19 results

Testing effectiveness (Phase 2)UnknownNCT06270225
What this trial is testing

SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment.

Who this might be right for
Gout Arthritis
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. 157
Post-approval studies (Phase 4)Looking for participantsNCT07346079
What this trial is testing

Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares

Who this might be right for
Gout ArthritisGout FlareGout
Massachusetts General Hospital 150
Large-scale testing (Phase 3)Study completedNCT01470989
What this trial is testing

Β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)

Who this might be right for
Acute Gouty Arthritis Flares
Novartis Pharmaceuticals 136
Testing effectiveness (Phase 2)Study completedNCT01712204
What this trial is testing

A Proof-of-Concept Study of AC-201 to Prevent Gout Flares

Who this might be right for
Gout Flares
TWi Biotechnology, Inc. 82
Testing effectiveness (Phase 2)Looking for participantsNCT07145229
What this trial is testing

Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare

Who this might be right for
Acute Gouty ArthritisGout FlareGout Flares+1 more
Atom Therapeutics Co., Ltd 380
Large-scale testing (Phase 3)Study completedNCT05983445
What this trial is testing

Safety & Efffficacy of Genakumab in Patients With Frequent Flares

Who this might be right for
Acute Gout Arthritis
Changchun GeneScience Pharmaceutical Co., Ltd. 313
Testing effectiveness (Phase 2)Study completedNCT00927810
What this trial is testing

Long Term Study of Canakinumab (ACZ885) in Patients With Gout

Who this might be right for
Gouty Arthritis
Novartis Pharmaceuticals 341
Large-scale testing (Phase 3)Study completedNCT01356602
What this trial is testing

Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

Who this might be right for
Acute Gouty Arthritis
Novartis Pharmaceuticals 397
Large-scale testing (Phase 3)WithdrawnNCT01593527
What this trial is testing

Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease

Who this might be right for
Acute Gouty Arthritis
Novartis Pharmaceuticals
Large-scale testing (Phase 3)Ended earlyNCT01362608
What this trial is testing

Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective

Who this might be right for
Gouty Arthritis
Novartis Pharmaceuticals 136
Not applicableUnknownNCT04069325
What this trial is testing

Efficacy and Safety of Simiaowan in Prevention of Acute Flares in Chronic Gout Patients Initiating Febuxostat Therapy

Who this might be right for
Gout Flare
Guang'anmen Hospital of China Academy of Chinese Medical Sciences 72
Large-scale testing (Phase 3)Study completedNCT01029652
What this trial is testing

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study

Who this might be right for
Acute Gout
Novartis Pharmaceuticals 230
Testing effectiveness (Phase 2)Study completedNCT00819585
What this trial is testing

The Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)

Who this might be right for
Gout
Novartis Pharmaceuticals 432
Post-approval studies (Phase 4)Study completedNCT00170781
What this trial is testing

Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout

Who this might be right for
Acute Gouty Arthritis
Novartis 234
Not applicableUnknownNCT05744297
What this trial is testing

NLRP3 Inflammasome Activation Among Patients During Acute Gout Flares

Who this might be right for
Gout Arthritis
Centre Hospitalier Saint Joseph Saint Luc de Lyon 10
Early research (Phase 1)Study completedNCT06258213
What this trial is testing

Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers

Who this might be right for
GoutAcute Gout FlareGout Flares
Atom Therapeutics Co., Ltd 90
Testing effectiveness (Phase 2)Study completedNCT00798369
What this trial is testing

Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients

Who this might be right for
Acute Gout
Novartis 200
Large-scale testing (Phase 3)Study completedNCT01431638
What this trial is testing

Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

Who this might be right for
Acute Gouty Arthritis
Novartis Pharmaceuticals 397
Large-scale testing (Phase 3)Study completedNCT01080131
What this trial is testing

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.

Who this might be right for
Acute Gout
Novartis Pharmaceuticals 226